← FDA Drug Approvals (Drugs@FDA)

EMPAGLIFLOZIN AND LINAGLIPTIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: PRINSTON PHARMA INC · Approved 2022-01-20

Drug application

FDA Application #

ANDA212264

Application type

Abbreviated New Drug Application (Generic)

Brand name

EMPAGLIFLOZIN AND LINAGLIPTIN

Generic name

Empagliflozin

Active ingredients

EMPAGLIFLOZIN; LINAGLIPTIN

Dosage form

TABLET

Route

ORAL

Marketing status

None (Tentative Approval)

Sponsor

PRINSTON PHARMA INC

First approval

2022-01-20

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown